Quince Therapeutics is on track for a pivotal readout of its NEAT Phase 3 trial in Ataxia-Telangiectasia (A-T) in mid-Q1 2026, targeting children aged 6–9. The trial has been redesigned to address previous statistical limitations and is now 90% powered to detect a clinically meaningful reduction in neurological decline. eDSP, Quince’s lead asset, employs chronic corticosteroid delivery via encapsulation in patient red blood cells, aiming to reduce systemic toxicity. With no approved therapies for A-T, the company estimates the addressable orphan market exceeds $1 billion annually. Interactions with FDA and EMA to date indicate strong alignment on trial endpoints and safety monitoring.

Seven brokerages cover Quince, collectively assigning a consensus rating of “Moderate Buy.” The breakdown includes one sell recommendation, one hold, four buys and one strong buy. Analysts’ average 12-month price objective stands at $8.00. Notable recent updates include D. Boral Capital raising its target from $4.00 to $5.00 with a buy rating, Weiss Ratings maintaining an e+ sell recommendation, and Citigroup reaffirming a market outperform stance in early January.

In its most recent quarter, the company reported a loss per share of $0.25, missing the consensus estimate of a $0.20 loss by $0.05. For the full year, analysts project a loss of $1.21 per share. Quince’s market capitalization is approximately $150 million, with a negative P/E ratio of 2.22 and a beta of 1.15. Institutional ownership totals 30.75%, with recent activity including XTX Topco Ltd acquiring a $37,000 stake; GSA Capital Partners increasing its holding by 158% to 87,235 shares (valued at $142,000); Bridgeway Capital Management adding 22,200 shares to reach 128,617 shares ($212,000); Rockefeller Capital Management initiating a $280,000 position; and Union Square Park Capital Management boosting its stake by 86% to 224,746 shares ($366,000).

Beyond eDSP, Quince’s proprietary AIDE platform combines an automated red blood cell encapsulation process with a single-use consumable kit (EryKit) and sterile delivery system. This technology is designed to extend drug half-life and minimize systemic exposure. Management highlights the platform’s modular design as a potential enabler for multiple indications in rare neurodegenerative and immunodeficiency disorders, positioning Quince to expand its pipeline once NEAT readout confirms proof-of-concept.